Analysts’ Weekly Ratings Changes for Bristol Myers Squibb (BMY)

Bristol Myers Squibb (NYSE: BMY) recently received a number of ratings updates from brokerages and research firms:

• 12/23/2025 – Bristol Myers Squibb had its “buy” rating reaffirmed by analysts at Guggenheim.
• 12/15/2025 – Bristol Myers Squibb was upgraded by analysts at Bank of America Corporation from a “neutral” rating to a “buy” rating. They now have a $61.00 price target on the stock, up previously from $52.00.
• 12/12/2025 – Bristol Myers Squibb had its “underweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $37.00 price target on the stock, up previously from $36.00.
• 12/10/2025 – Bristol Myers Squibb had its “hold” rating reaffirmed by analysts at HSBC Holdings plc. They now have a $53.00 price target on the stock.
• 12/10/2025 – Bristol Myers Squibb had its price target raised by analysts at Wells Fargo & Company from $53.00 to $55.00. They now have an “equal weight” rating on the stock.
• 12/4/2025 – Bristol Myers Squibb had its “sector perform” rating reaffirmed by analysts at Scotiabank. They now have a $53.00 price target on the stock, up previously from $45.00.
• 12/3/2025 – Bristol Myers Squibb was given a new $65.00 price target on by analysts at Truist Financial Corporation.
• 12/2/2025 – Bristol Myers Squibb had its “neutral” rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $57.00 price target on the stock, up previously from $51.00.
• 11/24/2025 – Bristol Myers Squibb had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald.
• 11/17/2025 – Bristol Myers Squibb had its “market perform” rating reaffirmed by analysts at BMO Capital Markets.
• 11/17/2025 – Bristol Myers Squibb had its price target lowered by analysts at Citigroup Inc. from $48.00 to $45.00. They now have a “neutral” rating on the stock.
• 11/13/2025 – Bristol Myers Squibb is now covered by analysts at Scotiabank. They set a “sector perform” rating and a $45.00 price target on the stock.
• 11/12/2025 – Bristol Myers Squibb was upgraded by analysts at Scotiabank to a “hold” rating.
• 11/8/2025 – Bristol Myers Squibb was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 11/3/2025 – Bristol Myers Squibb had its “market perform” rating reaffirmed by analysts at Sanford C. Bernstein.

Bristol Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.6%. The ex-dividend date is Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio is 83.78%.

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.